Efficient antibody evasion but reduced ACE2 binding by the emerging SARS-CoV-2 variant B.1.640.2
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2042-0226
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Efficient antibody evasion but reduced ACE2 binding by the emerging SARS-CoV-2 variant B.1.640.2 ; volume:19 ; number:9 ; day:17 ; month:5 ; year:2022 ; pages:1067-1069 ; date:9.2022
Cellular & molecular immunology ; 19, Heft 9 (17.5.2022), 1067-1069, 9.2022
- Creator
-
Arora, Prerna
Kempf, Amy
Nehlmeier, Inga
Graichen, Luise
Schulz, Sebastian
Cossmann, Anne
Jablonka, Alexandra
Winkler, Martin S.
Jäck, Hans-Martin
Behrens, Georg Martin Norbert
Pöhlmann, Stefan
Hoffmann, Markus
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41423-022-00870-5
- URN
-
urn:nbn:de:101:1-2022111621080099741588
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:24 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Arora, Prerna
- Kempf, Amy
- Nehlmeier, Inga
- Graichen, Luise
- Schulz, Sebastian
- Cossmann, Anne
- Jablonka, Alexandra
- Winkler, Martin S.
- Jäck, Hans-Martin
- Behrens, Georg Martin Norbert
- Pöhlmann, Stefan
- Hoffmann, Markus
- SpringerLink (Online service)
Other Objects (12)
Antibody neutralization of SARS-CoV-2 through ACE2 receptor mimicry
Force-tuned avidity of spike variant-ACE2 interactions viewed on the single-molecule level
The immune evasion ability of Delta variant is comparable to that of Beta variant in South Africa
Antibody Fc-binding profiles and ACE2 affinity to SARS-CoV-2 RBD variants
Evasión.
Inactivated whole virion vaccine protects K18‐hACE2 Tg mice against the Omicron SARS‐CoV‐2 variant via cross‐reactive T cells and nonneutralizing antibody responses
Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5
Variant-proof high affinity ACE2 antagonist limits SARS-CoV-2 replication in upper and lower airways
Delta (B1.617.2) variant of SARS-CoV-2 induces severe neurotropic patterns in K18-hACE2 mice
Human recombinant soluble ACE2 (hrsACE2) shows promise for treating severe COVID19
La evasión
La evasión
Antibody neutralization of SARS-CoV-2 through ACE2 receptor mimicry
Force-tuned avidity of spike variant-ACE2 interactions viewed on the single-molecule level
The immune evasion ability of Delta variant is comparable to that of Beta variant in South Africa
Antibody Fc-binding profiles and ACE2 affinity to SARS-CoV-2 RBD variants
Evasión.
Inactivated whole virion vaccine protects K18‐hACE2 Tg mice against the Omicron SARS‐CoV‐2 variant via cross‐reactive T cells and nonneutralizing antibody responses
Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5
Variant-proof high affinity ACE2 antagonist limits SARS-CoV-2 replication in upper and lower airways
Delta (B1.617.2) variant of SARS-CoV-2 induces severe neurotropic patterns in K18-hACE2 mice
Human recombinant soluble ACE2 (hrsACE2) shows promise for treating severe COVID19
La evasión
La evasión
Antibody neutralization of SARS-CoV-2 through ACE2 receptor mimicry
Force-tuned avidity of spike variant-ACE2 interactions viewed on the single-molecule level
The immune evasion ability of Delta variant is comparable to that of Beta variant in South Africa
Antibody Fc-binding profiles and ACE2 affinity to SARS-CoV-2 RBD variants
Evasión.
Inactivated whole virion vaccine protects K18‐hACE2 Tg mice against the Omicron SARS‐CoV‐2 variant via cross‐reactive T cells and nonneutralizing antibody responses
Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5
Variant-proof high affinity ACE2 antagonist limits SARS-CoV-2 replication in upper and lower airways
Delta (B1.617.2) variant of SARS-CoV-2 induces severe neurotropic patterns in K18-hACE2 mice
Human recombinant soluble ACE2 (hrsACE2) shows promise for treating severe COVID19
La evasión